PubMed Health⌕ Search

Biomedical subjects

A Maynard

Publications and source records attributed to A Maynard.

At least 55 records · Page 3Linked to original sources

Economic evaluation techniques in healthcare. Reinventing the wheel?

Application of the technique of economic evaluation has increased markedly in the past 5 years. Literature on the techniques of economic evaluation is over 30 year old, and the principal architect of such techniques in Britain is Professor Alan Williams of the University of York. In 1974 he wrote a 'checklist of questions' to apply to economic studies. These questions have since been elaborated by Mike Drummond and colleagues, and by the end of the 1980s guidelines were well articulated. Since this time there have been substantial investments in 'gilding the lily', leading to marginal improvements. This investment in 'reinventing the wheel' could more usefully be applied to resolution of contentious areas where there is still a lack of consensus. It is time to stop going around in circles with guideline reiteration and quasi-consensus statements, and instead target resources where they give the greatest return to knowledge.

Delivery of Health Care↗

Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry.

This is the third of three papers that review international policies to control spending on drugs and to improve the efficiency of drug use. This paper reviews policies regulating the supply of drugs, particularly licensing and reimbursement controls, price and profit regulation. Price and profit controls contain few incentives for improving cost effective use of drugs, and focus on cost containment and profitability of domestic industry. Carefully monitored economic evaluation could lead to improvements in efficiency and benefits to patients and the health care system.

Cost-Benefit Analysis↗

An economic exploration of oral and intravenous ganciclovir in the induction and maintenance treatment of AIDS-related cytomegalovirus retinitis.

The objective of the study was to compare the impact of oral and i.v. ganciclovir on resource use and direct health care costs, from the perspective of the UK National Health Service (NHS). The analytical framework used was cost analysis. The sources of data were an open, randomized clinical trial, and additional research which collected resource use and cost data. From the perspective of the UK NHS, the expected cost of i.v. ganciclovir for initial induction and 140 days maintenance and reinduction therapy was pounds 730 higher than that of oral (pounds 8145 vs pounds 7415). Conservative estimates which did not favour oral ganciclovir were used wherever possible. Overall, the resource use and costs of maintenance therapy with oral ganciclovir calculated in the model used for this study were lower than those of i.v. ganciclovir, principally reflecting lower costs for the administration of therapy. In this model the drug cost of ganciclovir maintenance therapy was excluded.

AIDS-Related Opportunistic Infections↗

Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs?

Nonsteroidal anti-inflammatory drugs (NSAIDs) are used widely throughout the world to relieve the symptoms of musculoskeletal disorders, in particular osteoarthritis and rheumatoid arthritis. These drugs have significant adverse effects, including gastrointestinal ulceration and the associated complications of perforation and bleeding. The relative toxicity of competing forms of branded and generic NSAIDs varies considerably. Their acquisition cost also varies considerably, sometimes with relatively more toxic drugs being more expensive. Thus, it may be possible to reduce both adverse effects and pharmaceutical expenditures associated with NSAIDs, if doctors' prescribing behaviour can be changed. A tentative exploration of alternative patterns of NSAID use demonstrates that it may be possible to reduce expenditures on NSAIDs in the UK to below the 1994 level, and reduce adverse events. If prescribing of NSAIDs was reduced by 25%, average dosage reduced by 10% and patients switched to less toxic NSAIDs, up to 86 million pounds sterling could be saved per year in the UK, the number of serious adverse events per year reduced by 189 (from a baseline figure of around 500) and the annual number of gastrointestinal complications reduced by 127 (from a baseline figure of around 315). Such results may be achieved without reductions in the quality of life of patients using these drugs. The available clinical and economic information about NSAIDs is limited, and the publication of numerous poor quality studies has corrupted the knowledge base. Despite these problems, there appears to be enough evidence to indicate that expenditure on NSAIDs could be considerably reduced and significant adverse effects could be avoided if general practitioners were persuaded to change their prescribing behaviour. Inefficient and inappropriate prescribing of these often beneficial, but sometimes dangerous, drugs appears to be wasting scarce UK National Health Service resources and harming patients.

Anti-Inflammatory Agents, Non-Steroidal↗

Managing the medical workforce: time for improvements?

There has been a regular cycle of Government committees in Britain that have forecast 'shortages' and 'surpluses' in medical manpower. It is remarkable how little change there has been in the methods used in these forecasts despite criticism of their methods and the move towards competitive markets in the delivery of health care. The practice of medical manpower planning was criticised in the 1960s because of the failure to explore the implications of alternative skill mixes and incentives. Whilst these criticisms were ignored, the forecasters now pay more regard to budget constraints and produce more regular estimates. The 1992 forecast could be improved by sensitivity analysis (e.g. for GP/population ratios). However, unless the issue of scope (forecasting for all health care staff, not just for doctors alone) and the implications of skill mix and incentives identified in the 1960s are addressed effectively, the current recommendations may produce doctor 'surpluses' in the early twenty-first century. The Government's analysis should be challenged at the level of principle and practice, and this implies that the research activity proposed in the 1960s is carried out in the 1990s to facilitate efficiency in the twenty-first century. Furthermore, the issue of policy priorities and their ranking needs to be spelt out explicitly: does the Government want a competitive NHS internal market, and if it does, what is the role of central manpower planning? One implication of current policy choice and the maintenance of manpower planning is that cost containment is of more importance to policy makers than the internal market.

Forecasting↗

Primary care and health care reform: the need to reflect before reforming.

The system of primary care in the UK National Health Service appears to have become popular amongst policy makers worldwide. This is surprising given the poor knowledge base regarding the care provided and its cost effectiveness. It is necessary for policy makers to identify which health care interventions are effective and cost effective, and develop knowledge about how behaviour can be changed and cost effective interventions adopted in routine medical practice. Trials of pharmaceuticals in primary care therapeutic areas reveal a poor knowledge base about clinical effectiveness and often fail to include economic aspects. Initiatives such as the UK general practice fundholding scheme, the general practitioner contract and the Health of the Nation targets were not based on empirical evidence and have not been subject to adequate evaluation. If health care reforms elsewhere are to include emphasis on primary care, policy goals must be clearly articulated and the knowledge base informing efficient delivery of primary care must be improved.

Cost-Benefit Analysis↗

Help or hindrance? The role of economics in rationing health care.

The economic evaluation of alternative diagnostic and therapeutic interventions is not merely a help to the processes by which decision makers allocate scarce economic resources, it is an essential ingredient into those rationing processes. Clinicians and other decision makers who advocate the use of effectiveness data alone to determine who will be treated and who will be left in pain and discomfort may perpetuate the inefficient use of resources. Rationing, or resource allocation, in health care must be informed by knowledge of the costs and consequences (effects) or alternative interventions. To ignore the economic element in clinical choices, generates inefficiency, and therefore unethical practice. The great advantage of the economic approach to rationing is that it requires an explicit framework which identifies the costs and benefits of alternative actions in all domains of human action. The combination of explicitness and precision inherent in good economic evaluation can only help in the difficult task of producing further health benefits for patients from the limited resources of the NHS.

Health Care Rationing↗